Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers
NCT ID: NCT01987011
Last Updated: 2015-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
420 participants
INTERVENTIONAL
2013-08-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers
NCT01389466
Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)
NCT02249221
A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine
NCT01201902
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults
NCT03357263
A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older
NCT02917304
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MG1109
MG1109 0.5 mL Intramuscularly injection, twice at an interval of 21 days
MG1109
Placebo
Placebo(for MG1109) 0.5 mL Intramuscularly injection, twice at an interval of 21 days
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MG1109
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects with immune system disorder including immune deficiency disease
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korean Center for Disease Control and Prevention
OTHER_GOV
Green Cross Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Woo Joo Kim, MD, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Ansan Hospital
Ansan, , South Korea
Inha University Hospital
Inchon, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Catholic University Of Korea ST. Vincent's Hospital
Suwon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MG1109_P3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.